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Objectives: We identiﬁed Candida spp isolated from lower respiratory tract secretions obtained from
cystic ﬁbrosis (CF) patients, by matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS), with the aim of determining the most prevalent causative agent. We
also sought to determine their adhesive properties in order to understand their biology related to CF.
Methods: Twenty-ﬁve clinical samples were collected from a cohort of 20 CF patients. Twenty-six
isolates of Candida spp were isolated and identiﬁed by MALDI-TOF MS method. Adherence assays were
performed using the Fluxion BioFlux 200, a ﬂow apparatus that allows for the visualization of adhering
cells.
Results: MALDI-TOF MS analysis revealed C. dubliniensis to be the most prevalent species (n = 18, 69%),
followed by C. albicans (n = 4), C. tropicalis (n = 3), and C. glabrata (n = 1). C. dubliniensis showed the
strongest adherence under constant ﬂow when compared to the other species of Candida. In the majority
of cases, C. dubliniensis was isolated in combination with Pseudomonas aeruginosa and Staphylococcus
aureus. C. dubliniensis appears to be able to survive in the CF lung and coexist with bacteria.
Conclusions: The data presented here show that the presence of C. dubliniensis in the lower airways of CF
patients may be related to increased adherence properties.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Cystic ﬁbrosis (CF) is the major genetic inherited disease found
in European Caucasians, but is common worldwide.1 CF occurs due
to mutations in the cystic ﬁbrosis transmembrane conductance
regulator gene (CFTR), which results in a defective mucociliaryciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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mucus. This mucus facilitates the entrapment of airborne bacteria
and fungal conidia, providing an environment suitable for the
growth of these microorganisms.2
Signiﬁcant risk factors for CF patients that predispose them to
increased oral Candida colonization include steroid use, CF-related
diabetes, and recurrent courses of prolonged antibiotic treatment.3
The airways of CF patients are often colonized by bacterial
species that cause chronic infections. Among these bacteria,
Pseudomonas aeruginosa and Staphylococcus aureus are the
predominant species, followed by Burkholderia cepacia and
Haemophilus inﬂuenzae.2,4 Candida spp are the most common
yeasts isolated from the airways of CF patients.5,6 In a German
study, C. albicans was isolated with a high frequency (78.8%) from
the respiratory tract of CF patients, whereas C. dubliniensis has been
isolated with a lower frequency; however little is known about its
potential to cause disease in these patients.7
The identiﬁcation of C. dubliniensis in particular remains
problematic due to its close relatedness and phenotypic similarity
to C. albicans.5 Differences between these two species are most
pronounced at the genetic level and for that reason molecular
methods are more accurate to distinguish C. albicans from C.
dubliniensis.8 Matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF MS) is now considered as
reliable as molecular diagnostics, and is applied routinely for the
identiﬁcation of yeast due to its potential to differentiate closely
related species. The differentiation of C. albicans and C. dubliniensis
is of importance in order to better understand the epidemiology
and virulence of C. dubliniensis.6 C. dubliniensis is only a minor
component of the normal microbiota of oral cavities, but is
distributed worldwide.7 In recent years, however, the isolation of
C. dubliniensis has increasingly been reported from patients with
candidemia and CF patients.9,10 The prevalence rate of this
emerging pathogen among CF patients has been shown to range
from 2.6% to 39%.11,12
In this article we report the high and frequent occurrence of C.
dubliniensis in the respiratory secretions of CF patients from Qatar.
The aim of this study was to identify Candida spp isolated from
pediatric and adult CF patients, by MALDI-TOF MS method, to
determine the most prevalent causative agent. In addition we
examined their adhesive properties to understand how this aspect
of their biology relates to CF.
2. Materials and methods
2.1. Patients and sampling
Over a period of 2 years, sputum samples, deep pharyngeal
swabs (taken from patients who did not produce sputum), and
bronchoalveolar lavage (BAL) samples were collected from
pediatric and adult CF patients at Hamad Medical Corporation,
Doha, Qatar. The diagnosis of CF was based on one or more clinical
features consistent with CF, namely positive family history of CF in
siblings and close relatives, elevated sweat chloride (> 60 mmol/l)
on two separate occasions, and the presence of two disease-
causing mutations in the CFTR gene.
2.2. Phenotypic identiﬁcation of Candida species
Samples of lower respiratory tract secretions were collected
and immediately cultured on Sabouraud dextrose agar plates with
chloramphenicol (SDAC) (Difco, USA) and CHROMagar Candida
plates (Oxoid Ltd, UK) to isolate yeasts and to ensure purity of the
isolates. SDAC plates were incubated at 35 8C and CHROMagar
Candida plates at 30 8C for 48 h. Candida isolates were processed
using the VITEK 2 Compact yeast identiﬁcation system (bioMe´r-ieux, France). All isolates were preserved at 70 8C using cryotubes
(Mast Diagnostics, UK), and were later identiﬁed by MALDI-TOF MS
at the CBS-KNAW Fungal Biodiversity Centre, Utrecht,
Netherlands.
2.3. Biochemical identiﬁcation of bacterial isolates
Clinical specimens were cultured on a variety of different media
(Remel, Lenexa, KS, USA) including trypticase soy blood agar with
5% sheep blood (TSA), chocolate agar (CHOC), MacConkey agar
(MAC), mannitol salt agar (MS), and B. cepacia selective agar
(BCSA). Plates were incubated in ambient air or 5% CO2 at 35 8C and
examined daily until all isolates were identiﬁed. A single colony of
each isolate was identiﬁed by VITEK 2 Compact (bioMe´rieux) or
Phoenix 100 (Franklin lakes, NJ, USA). After 2 days of incubation at
35 8C, lactose-negative and oxidase-positive colonies of P. aerugi-
nosa were selected and identiﬁed, as described previously,13 using
P. aeruginosa reference strain ATCC 27853.
2.4. MALDI-TOF mass spectrometry
Each clinical isolate of Candida spp was maintained on GYPA
plates (2% glucose, 0.5% yeast extract, 1% peptone, 1.5% agar) for
48 h at 30 8C. A single colony was isolated and subcultured on SDA
plates for 24 h at 30 8C. Isolates were identiﬁed by MALDI-TOF MS
carried out according to the Bruker Daltonics protocol, as reported
previously.14 To ensure reproducibility of the spectra, tested
isolates were measured in duplicate and identiﬁed by MALDI
Biotyper RTC software 3.0 (Bruker Daltonics, Germany). This
research was carried out using two databases: the original,
commercially available Bruker Daltonics database (BDAL) of
4110 main mass spectra (MSPs) and in addition a CBS-KNAW
in-house library of 510 MSPs of reference strains of different
yeasts.
2.5. Yeast cell adherence assay
Adherence assays were performed as described previously
using the Fluxion BioFlux 200 (Fluxion Biosciences), a ﬂow
apparatus that allows for the visualization of adhering cells.15
All clinical isolates were run in triplicate. For three Candida spp, a
species-speciﬁc reference strain was assayed, namely C. albicans
ATCC 90028, C. dubliniensis CBS 8500, and C. tropicalis ATCC 66029
as controls, and included in the experiment. The average number of
adhering cells for each strain was calculated based on three
replicates, and the average fold change was calculated (number of
adhering cells of the clinical isolate/the number of adhering cells of
C. albicans control reference strain). Error bars represent the
standard deviation and p-values were calculated by t-test.
3. Results
3.1. Clinical results
In this study, 25 respiratory samples were collected from 20 CF
patients of both genders (46% female and 54% male) aged 0.6–24
years (median 15.5 years) (Table 1). Additionally, three respiratory
samples were collected from patient 1 and two from patients 9, 14,
and 15. Eighteen patients of Qatari origin harbored the I1234 V
mutation in the CFTR gene associated with pancreatic sufﬁciency,
one patient of Bangladeshi origin had the deltaF508 mutation, and
the remaining patient of Pakistani origin had an undetermined CF
genotype due to an unknown CFTR gene mutation. Additionally, 14
patients received anti-Pseudomonas nebulized antibiotic prophy-
laxis with tobramycin (n = 13) and gentamicin (n = 1). The patients
of Bangladeshi and Pakistani origin had pancreatic insufﬁciency.
Table 1
Demographic data and Candida species isolated from respiratory specimens obtained from cystic ﬁbrosis patients
Patient No. Date of specimen
collection
Clinical
specimen
Prophylaxis with
nebulized antibiotic
Age (years)/
gender
CHROMagar Candida
identiﬁcation/VITEK 2
MALDI-TOF MS
identiﬁcation
1 10/27/09 Sputum Tobramycin 16/M C. albicans C. dubliniensis
4/9/10 Sputum Tobramycin 16/M C. dubliniensis C. dubliniensis
10/6/10 Sputum Tobramycin 16/M C. dubliniensis C. dubliniensis
2 8/12/10 BAL Tobramycin 22/M C. tropicalis C. tropicalis
3 10/12/10 Sputum Tobramycin 14/M Candida spp C. dubliniensis
4 3/21/11 Sputum Tobramycin 16/F C. albicans C. dubliniensis
5 3/24/11 Sputum Tobramycin 21/F C. albicans C. dubliniensis
6 8/3/11 Sputum None 22/F C. dubliniensis C. dubliniensis
7 8/18/11 Sputum Tobramycin 21/M C. dubliniensis C. dubliniensis
8 3/22/11 Pharyngeal
swab/ secretion
Gentamicin 3/M Candida spp C. glabrata
C. tropicalis C. tropicalis
9 10/12/10 Sputum Tobramycin 11/M Candida spp C. dubliniensis
2/1/11 Sputum Tobramycin 11/M C. dubliniensis C. dubliniensis
10 3/21/11 Sputum Tobramycin 18/F C. albicans C. dubliniensis
11 3/21/11 Sputum Tobramycin 15/F C. albicans C. albicans
12 9/22/10 Sputum Tobramycin 18/M C. dubliniensis C. dubliniensis
13 3/22/11 Pharyngeal
swab/ secretion
None 2/M C. albicans C. albicans
14 6/30/10 Sputum Tobramycin 15/F C. dubliniensis C. dubliniensis
8/18/11 Sputum Tobramycin 16/F C. albicans C. dubliniensis
15 11/9/10 Pharyngeal swab None 0.6/F C. tropicalis C. tropicalis
3/22/11 Pharyngeal swab None 1/F C. tropicalis C. albicans
16 4/9/11 Sputum Tobramycin 22/M C. albicans C. dubliniensis
17 7/19/11 Sputum None 11/M C. albicans C. dubliniensis
18 8/18/11 Sputum Tobramycin 24/M C. dubliniensis C. dubliniensis
19 9/27/10 BAL Tobramycin 5/F C. albicans C. albicans
20 3/21/11 Sputum None 9/F C. albicans C. dubliniensis
MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry; M, male; F, female; BAL, bronchoalveolar lavage.
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3.2. Yeast identiﬁcation
Twenty-six yeast isolates were recovered from 25 respiratory
samples of 20 CF patients over 2 years. MALDI-TOF MS analysis
revealed that the set of clinical isolates contained mainly C.
dubliniensis (n = 18), followed by C. albicans (n = 4), C. tropicalis
(n = 3), and C. glabrata (n = 1) (Table 1). All isolates were identiﬁedTable 2
Summary of demographic parameters and the bacteria co-existing with Candida specie
Organism
C. dubliniensis C. albicans
Isolates, n (%) 18 (69%) 4 (15%) 
Age
<18 years 11 (42%) 4 (15%) 
18 years 7 (27%) 0 
Gender
Male 10 (38%) 1 (4%) 
Female 8 (31%) 3 (12%) 
Specimen
BAL 0 1 (4%) 
Sputum 15 (58%) 4 (15%) 
Pharyngeal swab 0 2 (8%) 
Co-existing bacteria
Pseudomonas aeruginosa 12 (46%) 1 (4%) 
Staphylococcus aureus 8 (31%) 2 (8%) 
Haemophilus inﬂuenzae 3 (12%) 0 
Haemophilus parainﬂuenzae 0 1 (4%) 
Achromobacter sp. 1 (4%) 0 
Serratia rubidaea 1 (4%) 0 
BAL, bronchoalveolar lavage.with a score >2.0 on at least one spot from duplicates, and only two
runs were necessary to achieve 100% correct identiﬁcations.
A greater diversity of Candida spp was found in the group of
younger patients (<18 years old): C. dubliniensis (42%), C. albicans
(15%), C. tropicalis (8%), and C. glabrata (4%). The data presented in
Table 2 indicate that the highest number of Candida spp was
recovered from sputum. A 9-year-old female was the youngest CF
patient in whom C. dubliniensis was identiﬁed from sputum.
Additionally, one patient (patient 8, Table 1) was colonized withs
 C. tropicalis C. glabrata Total
3 (12%) 1 (4%) 26 (100%)
2 (8%) 1 (4%) 18 (69%)
1 (4%) 0 8 (31%)
2 (8%) 1 (4%) 14 (54%)
1 (4%) 0 12 (46%)
1 (4%) 0 2 (8%)
0 0 19 (73%)
2 (8%) 1 (4%) 5 (19%)
1 (4%) 0 14 (54%)
1 (4%) 0 11 (42%)
0 0 3 (12%)
0 0 1 (4%)
0 0 1 (4%)
0 0 1 (4%)
Figure 1. Relative adherence of Candida species isolates from lower respiratory tract secretions obtained from cystic ﬁbrosis patients in Qatar. CA, C. albicans; CD, C.
dubliniensis; CT, C. tropicalis.
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same pharyngeal swab sample.
3.3. Co-existing bacteria
A routine procedure was the identiﬁcation of bacterial
organisms accompanying the Candida spp in the airways of CF
patients. The presence of multiple bacterial species was found for
the majority of these patients: P. aeruginosa, S. aureus, H. inﬂuenzae,
Haemophilus parainﬂuenzae, Achromobacter sp, and Serratia rubi-
daea. P. aeruginosa and S. aureus were found to co-exist with 46%
and 31% of C. dubliniensis cases, respectively, rather than with
C. albicans (Table 2). All S. aureus isolates were found to be
methicillin-susceptible (MSSA).
3.4. Adherence assay
In order to detect whether adherence is a factor contributing to
the increased presence of C. dubliniensis in CF patients, all clinical
isolates were assayed for adherence. Adherence was measured as
the adherence ratio of the clinical isolate over the adherence of C.
albicans reference strain ATCC 90028. All isolates were compared
to C. albicans, as it represents the most frequently isolated fungalFigure 2. Microscope images of yeast cells adhering under ﬂow after 30 min. Increased
compared to C. albicans (left panel).pathogen in the clinical setting.16 The data showed that adherence
varied greatly within tested Candida spp and between the different
isolates (Figure 1). C. dubliniensis isolates showed higher adherence
capability in comparison to C. albicans (Figure 2). Eight of the C.
dubliniensis CF isolates showed statistically higher levels in
adherence when compared to the C. albicans reference strain. C.
tropicalis and C. albicans had similar levels of adherence as the C.
albicans reference strain (Figure 1).
When the adherence level was averaged between tested
isolates within species, isolates of C. dubliniensis showed a
signiﬁcantly increased adherence compared to C. tropicalis and
C. albicans (Figure 3).
4. Discussion
The frequent use of broad-spectrum antibiotics and the use of
oral or inhaled steroids predisposes CF patients to colonization of
the upper and lower airways with Candida spp. Recently, C. albicans
was reported to be the most prevalent yeast isolated from the
respiratory tract, found in 93–95% of CF patients.17 It remains
unknown whether Candida spp are only involved in oral carriage or
whether they can also be seen as transient or persistent colonizers
of the airways. An increase in the emergence of non-albicans numbers of adhering cells can be observed for C. dubliniensis (right panel) when
Figure 3. Comparison of the average relative adherence of three Candida species isolated from lower respiratory tract secretions obtained from cystic ﬁbrosis patients in Qatar.
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CF patients.17 Doern and Brogden-Torres reported non-albicans
Candida spp to account for 15% of all Candida isolates; the most
frequently found were C. tropicalis (6%), C. glabrata (5%), and C.
parapsilosis (4%).18 The disparity between the results presented in
this study and the results of Doern and Brogden-Torres are
explained by the fact that at the time of publication of the Doern
and Brogden-Torres article, C. dubliniensis had not been recognized
as a species independent from C. albicans.
In our study, the MALDI-TOF MS technique was applied and
reliable identiﬁcation results conﬁrmed that C. dubliniensis was the
most prevalent species (69%) isolated from CF patients in Qatar,
probably the result of the more species-sensitive method.
C. albicans and C. dubliniensis are closely related species that are
difﬁcult to distinguish by routine diagnostic methods. Thus it is
likely that many C. dubliniensis isolates have been incorrectly
identiﬁed as C. albicans when using traditional phenotypic
identiﬁcation methods, such as CHROMagar Candida. The in-
creased sensitivity and application of the MALDI-TOF MS
technique may provide new trends in the distribution of emerging
pathogenic Candida spp in CF and other patients. The differences in
prevalence rates of fungal species may also vary due to the lack of
standardized culture methods applied for CF specimen samples.8
The cause of the high rate of C. dubliniensis in CF patients in
Qatar is unknown. It has been reported that patients >30 years old
with more advanced CF are more frequently colonized by C.
albicans,19 but the present study revealed C. dubliniensis to be the
most prevalent in the sputum of patients younger than 18 years of
age. Interestingly, no C. dubliniensis was found in samples collected
from deep oropharyngeal swabs. One limitation of this study was
that the variation in different Candida spp isolated was dependent
on the number of clinical specimens, i.e. sputum, BAL, and
oropharyngeal swabs.
Cell surface hydrophobicity may play an important role in C.
dubliniensis virulence, as it promotes adhesion to the host
epithelial cell surface.20 Despite the fact that C. dubliniensis is
generally considered less pathogenic than C. albicans, it does have a
higher cell surface hydrophobicity than C. albicans and was isolated
more frequently in this study.20 Adherence is essential for C.dubliniensis colonization and may promote pathogenic actions, e.g.,
bioﬁlm formation, resulting in its ability to persist in the host and
evade antifungal treatment. The fact that C. dubliniensis was the
strongest adhering species is of interest, because C. dubliniensis is
reported as a frequent source of oropharyngeal candidiasis and has
the ability to ‘replace’ C. albicans during ﬂuconazole treatment.21
Undoubtedly, long-term colonization with C. dubliniensis and
other Candida spp contribute to the CF disease course. While
difﬁcult to interpret, the cross-kingdom interaction between yeast
and bacteria is of clinical importance and could potentially
contribute to the CF disease course. In this study, C. dubliniensis,
P. aeruginosa, and S. aureus were found frequently to co-exist in
sputum. As C. dubliniensis has a decreased ability to form hyphae
and persists mainly in the yeast form, the interaction between this
species and P. aeruginosa may differ from that between C. albicans
and P. aeruginosa. Many examples of C. albicans–bacteria relation-
ships exist and while most of the interactions are antagonistic (e.g.,
with P. aeruginosa), those of synergistic nature exist as well (e.g.,
with Staphylococcus epidermidis and oral streptococci). For exam-
ple, an in vitro polymicrobial bioﬁlm can be formed between S.
aureus and C. albicans. C. albicans forms the basal layer for such
bioﬁlms and S. aureus adheres to the fungal hyphae or forms micro-
colonies on the surface of the yeast bioﬁlm.22 Fungal–bacterial
interactions are usually combative resulting in one species
triumphing over the other. The fungal quorum sensing molecule
farnesol inhibits S. aureus bioﬁlm formation and increases S. aureus
antibiotic vulnerability.23,24 Bacteria also combat fungi; P.
aeruginosa secretes homoserine lactone, which mimics the quorum
sensing molecule farnesol, resulting in inhibition of ﬁlamentation
and bioﬁlm formation by C. albicans.25 Interestingly, in vitro
studies have indicated that P. aeruginosa adherence and bioﬁlm
formation are enhanced in the presence of C. albicans, which results
in an antagonistic relationship: fungal killing or limitation of C.
albicans growth in the host.26,27 No studies are available describing
the relationship and interactions between C. dubliniensis and
bacteria. The fact that C. dubliniensis was isolated in combination
with P. aeruginosa and S. aureus in all cases, indicates the possibility
that C. dubliniensis possesses mechanisms that allow it to survive
and coexist with bacteria that are usually detrimental to C. albicans.
A. Abdul Wahab et al. / International Journal of Infectious Diseases 24 (2014) 14–19 19In contrast to other reports, our data provide evidence for the
prevalence of C. dubliniensis over C. albicans in the lower respiratory
airways of CF patients. Our data also indicate that C. dubliniensis
may not only be associated with oral cavities of immunocompro-
mised patients, but also with the respiratory tract of CF patients.
Further attention should focus on the CF population to monitor the
existence of Candida spp over prolonged periods of time, along with
the bacterial species important for CF, such as P. aeruginosa and S.
aureus. This will allow the determination of the pathogenic role of
C. dubliniensis and how it contributes to disease progression in CF
patients. Additional studies are also necessary to investigate
whether an epidemiological trend of persistence of C. dubliniensis
and co-colonization with P. aeruginosa and S. aureus in the airways
of CF patients in Qatar is maintained and if this feature may be
related to the geographic distribution of these pathogenic yeast
species, or speciﬁc attributes, such as adhesion.
Acknowledgements
The study was reviewed and approved by the local ethics
committee, Medical Research Center at Hamad Medical Corpora-
tion. This publication was supported by an NPRP grant (5-298-3-
086) from the Qatar National Research Fund (a member of the
Qatar Foundation) to Atqah Abdul Wahab, Saad Taj-Aldeen, and
Teun Boekhout, and was also supported by an NPRP grant (6-1130-
3-267) to Jonathan S. Finkel and Saad Taj-Aldeen. The statements
herein are solely the responsibility of the authors.
Conﬂict of interest: All authors declare no conﬂict of interest.
References
1. Ratjen F, Doring G. Cystic ﬁbrosis. Lancet 2003;361:681–9.
2. Vonberg RP, Gastmeier P. Isolation of infectious cystic ﬁbrosis patients: results
of a systematic review. Infect Control Hosp Epidemiol 2005;26:401–9.
3. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, et al. Effect of
chronic intermittent administration of inhaled tobramycin on respiratory
microbial ﬂora in patients with cystic ﬁbrosis. J Infect Dis 1999;179:1190–6.
4. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic ﬁbrosis.
Clin Microbiol Rev 2002;15:194–222.
5. Citiulo F, Moran GP, Coleman DC, Sullivan DJ. Puriﬁcation and germination of
Candida albicans and Candida dubliniensis chlamydospores cultured in liquid
media. FEMS Yeast Res 2009;9:1051–60.
6. Hof H, Eigner U, Maier T, Staib P. Differentiation of Candida dubliniensis from C.
albicans by means of MALDI-TOF mass spectrometry. Clin Lab 2012;58:927–31.7. Loreto ES, Scheid LA, Nogueira CW, Zeni G, Santurio JM, Alves SH. Candida
dubliniensis: epidemiology and phenotypic methods for identiﬁcation. Myco-
pathologia 2010;169:431–3.
8. Muthig M, Hebestreit A, Ziegler U, Seidler M, Mu¨ller FM. Persistence of Candida
species in the respiratory tract of cystic ﬁbrosis patients. Med Mycol 2010;48:56–63.
9. Khan Z, Ahmad S, Joseph L, Chandy R. Candida dubliniensis: an appraisal of its
clinical signiﬁcance as a bloodstream pathogen. PLoS One 2012;7:e32952.
10. Gu¨ngo¨r O, Tamay Z, Gu¨ler N, Erturan Z. Frequency of fungi in respiratory
samples from Turkish cystic ﬁbrosis patients. Mycoses 2013;56:123–9.
11. Peltroche-Llacsahuanga H, Do¨hmen H, Haase G. Recovery of Candida dublinien-
sis from sputum of cystic ﬁbrosis patients. Mycoses 2002;45:15–8.
12. Gammelsrud KW, Sandven P, Høiby EA, Sandvik L, Brandtzaeg P, Gaustad P.
Colonization by Candida in children with cancer, children with cystic ﬁbrosis,
and healthy controls. Clin Microbiol Infect 2011;17:1875–81.
13. Abdul Wahab A, Taj-Aldeen SJ, Hagen F, Diophode S, Saadoon A, Meis JF, et al.
Genotypic diversity of Pseudomonas aeruginosa in cystic ﬁbrosis siblings in
Qatar using AFLP ﬁngerprinting. Eur J Clin Microbiol Infect Dis 2014;33:265–71.
14. Kolecka A, Khayhan K, Groenewald M, Theelen B, Arabatzis M, Velegraki A, et al.
Identiﬁcation of medically relevant species of arthroconidial yeasts by use of
matrix-assisted laser desorption ionization-time of ﬂight mass spectrometry. J
Clin Microbiol 2013;51:2491–500.
15. Finkel JS, Xu W, Huang D, Hill EM, Desai JV, Woolford CA, et al. Portrait of
Candida albicans adherence regulators. PLoS Pathog 2012;8:e1002525.
16. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent
public health problem. Clin Microbiol Rev 2007;20:133–63.
17. Chotirmall SH, O’Donoghue E, Bennett K, Gunaratnam C, O’Neill SJ, McElvaney
NG. Sputum Candida albicans presages FEV1 decline and hospital-treated
exacerbations in cystic ﬁbrosis. Chest 2010;138:1186–95.
18. Doern GV, Brogden-Torres B. Optimum use of selective plated media in primary
processing of respiratory tract specimens from patients with cystic ﬁbrosis. J
Clin Microbiol 1992;30:2740–2.
19. Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic ﬁbrosis: a
road less travelled. Med Mycol 2010;48(Suppl 1):114–24.
20. Borecka´-Melkusova´ S, Bujda´kova´ H. Variation of cell surface hydrophobicity
and bioﬁlm formation among genotypes of Candida albicans and Candida
dubliniensis under antifungal treatment. Can J Microbiol 2008;54:718–24.
21. Jabra-Rizk MA, Baqui AA, Kelley JI, Falkler Jr WA, Merz WG, Meiller TF.
Identiﬁcation of Candida dubliniensis in a prospective study of patients in the
United States. J Clin Microbiol 1999;37:321–6.
22. Harriott MM, Noverr MC. Candida albicans and Staphylococcus aureus form
polymicrobial bioﬁlms: effects on antimicrobial resistance. Antimicrob Agents
Chemother 2009;53:3914–22.
23. Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME. Effect of farnesol on Staphy-
lococcus aureus bioﬁlm formation and antimicrobial susceptibility. Antimicrob
Agents Chemother 2006;50:1463–9.
24. Kuroda M, Nagasaki S, Ito R, Ohta T. Sesquiterpene farnesol as a competitive
inhibitor of lipase activity of Staphylococcus aureus. FEMS Microbiol Lett
2007;273:28–34.
25. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule
inﬂuences Candida albicans morphology. Mol Microbiol 2004;54:1212–23.
26. McAlester G, O’Gara F, Morrissey JP. Signal-mediated interactions between
Pseudomonas aeruginosa and Candida albicans. J Med Microbiol 2008;57:563–9.
27. Holcombe LJ, McAlester G, Munro CA, Enjalbert B, Brown AJ, Gow NA, et al.
Pseudomonas aeruginosa secreted factors impair bioﬁlm development in Can-
dida albicans. Microbiology 2010;156:1476–86.
